A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α 2-containning GABAARs

Conclusion: By targeting nNOS-PSD-95 interaction and α2-containing GABAAR simultaneously, chronic use of ZL006-05 can avoid analgesic tolerance and unwanted side effects. Therefore, we offer a novel candidate drug without analgesic tolerance for treating neuropathic pain.

Source: Theranostics - April 19, 2021 Category: Molecular Biology Authors: Jun Li, Lin Zhang, Chu Xu, Ying-Ying Shen, Yu-Hui Lin, Yu Zhang, Hai-Yin Wu, Lei Chang, Ying-Dong Zhang, Rong Chen, Zheng-Ping Zhang, Chun-Xia Luo, Fei Li, Dong-Ya Zhu Tags: Research Paper Source Type: research